| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
22,052 |
21,654 |
$1.64M |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
12,737 |
12,551 |
$694K |
| 62323 |
|
368 |
365 |
$49K |
| 96132 |
|
393 |
393 |
$27K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
246 |
246 |
$25K |
| G0482 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed |
81 |
81 |
$14K |
| 01992 |
|
111 |
105 |
$13K |
| 96138 |
|
418 |
418 |
$7K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
65 |
65 |
$6K |
| 64493 |
|
40 |
40 |
$5K |
| J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg |
789 |
784 |
$5K |
| 80305 |
|
256 |
254 |
$3K |
| 64494 |
|
27 |
27 |
$2K |
| 62321 |
|
12 |
12 |
$2K |
| 99406 |
|
143 |
143 |
$2K |
| 27096 |
|
14 |
14 |
$2K |
| 64451 |
|
12 |
12 |
$2K |
| 99152 |
|
118 |
118 |
$1K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
20 |
20 |
$1K |
| 96127 |
|
180 |
180 |
$699.78 |
| G2011 |
Alcohol and/or substance (other than tobacco) misuse structured assessment (e.g., audit, dast), and brief intervention, 5-14 minutes |
303 |
302 |
$698.20 |
| J1040 |
Injection, methylprednisolone acetate, 80 mg |
40 |
40 |
$401.84 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
296 |
295 |
$316.32 |
| G8427 |
Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications |
14,139 |
13,902 |
$0.00 |
| G8417 |
Bmi is documented above normal parameters and a follow-up plan is documented |
3,394 |
3,336 |
$0.00 |
| G0444 |
Annual depression screening, 5 to 15 minutes |
150 |
150 |
$0.00 |
| G8420 |
Bmi is documented within normal parameters and no follow-up plan is required |
333 |
326 |
$0.00 |